Velaglucerase alfa

Drug Profile

Velaglucerase alfa

Alternative Names: GA-GCB; GCB; Gene-activated glucocerebrosidase; Glucocerebrosidase - Shire; Glucosylceramidase - Shire; Vpriv

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire
  • Class Glucosidases; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I
  • Phase I/II Gaucher's disease type III

Most Recent Events

  • 13 Apr 2015 Launched for Gaucher's disease type I in Australia and Canada (IV)
  • 13 Apr 2015 No recent reports on development identified - Phase-I/II for Gaucher's disease type I in Serbia (IV)
  • 13 Apr 2015 No recent reports on development identified - Phase-III for Gaucher's disease type I in Argentina, Paraguay, Russia, Tunisia, India and South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top